Free Trial

Cabaletta Bio (CABA) Stock Forecast & Price Target

Cabaletta Bio logo
$2.01 -0.25 (-11.06%)
(As of 12:30 PM ET)

Cabaletta Bio - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
0
Buy
10

Based on 10 Wall Street analysts who have issued ratings for Cabaletta Bio in the last 12 months, the stock has a consensus rating of "Buy." Out of the 10 analysts, 10 have given a buy rating for CABA.

Consensus Price Target

$27.30
1,258.21% Upside
According to the 10 analysts' twelve-month price targets for Cabaletta Bio, the average price target is $27.30. The highest price target for CABA is $50.00, while the lowest price target for CABA is $10.00. The average price target represents a forecasted upside of 1,258.21% from the current price of $2.01.
Get the Latest News and Ratings for CABA and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Cabaletta Bio and its competitors.

Sign Up

CABA Analyst Ratings Over Time

TypeCurrent Forecast
11/22/23 to 11/21/24
1 Month Ago
10/23/23 to 10/22/24
3 Months Ago
8/24/23 to 8/23/24
1 Year Ago
11/22/22 to 11/22/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
10 Buy rating(s)
10 Buy rating(s)
9 Buy rating(s)
9 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$27.30$28.10$30.11$26.90
Forecasted Upside1,258.21% Upside555.01% Upside396.88% Upside45.88% Upside
Consensus Rating
Buy
Buy
Buy
Buy

CABA Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

CABA Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Cabaletta Bio Stock vs. The Competition

TypeCabaletta BioMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.80
2.50
Consensus RatingBuyModerate BuyModerate Buy
Predicted Upside1,169.77% Upside27,482.23% Upside9.87% Upside
News Sentiment Rating
Neutral News

See Recent CABA News
Neutral News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/18/2024William Blair
2 of 5 stars
 Reiterated RatingOutperform
11/15/2024Wells Fargo & Company
3 of 5 stars
 Lower TargetOverweight ➝ Overweight$20.00 ➝ $12.00+288.35%
11/15/2024HC Wainwright
2 of 5 stars
 Reiterated RatingBuy ➝ Buy$25.00 ➝ $25.00+561.37%
10/10/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
T. Huynh
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$10.00+141.55%
8/12/2024Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
G. Clark-Gartner
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetOutperform ➝ Outperform$25.00 ➝ $15.00+231.13%
6/21/2024Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight ➝ Overweight$50.00 ➝ $50.00+459.28%
6/17/2024Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$32.00 ➝ $32.00+227.20%
4/4/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$26.00 ➝ $30.00+80.40%
2/5/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$36.00+63.41%
11/29/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$28.00 ➝ $25.00+66.22%
8/14/2023Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$34.00+151.11%
3/22/2023Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy$12.00+55.24%
3/17/2023Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy$10.00+29.03%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 12:59 PM ET.


CABA Forecast - Frequently Asked Questions

According to the research reports of 10 Wall Street equities research analysts, the average twelve-month stock price forecast for Cabaletta Bio is $27.30, with a high forecast of $50.00 and a low forecast of $10.00.

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cabaletta Bio in the last year. There are currently 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CABA shares.

According to analysts, Cabaletta Bio's stock has a predicted upside of 1,258.21% based on their 12-month stock forecasts.

Cabaletta Bio has been rated by research analysts at HC Wainwright, UBS Group, Wells Fargo & Company, and William Blair in the past 90 days.

Analysts like Cabaletta Bio more than other "medical" companies. The consensus rating for Cabaletta Bio is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how CABA compares to other companies.


This page (NASDAQ:CABA) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners